Open AccessSecond-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer
Author(s) -
Romain Altwegg
Publication year - 2012
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v18.i12.1357
Subject(s) - gemcitabine , medicine , regimen , chemotherapy , pancreatic cancer , clinical endpoint , gastroenterology , oncology , chemotherapy regimen , progression free survival , cancer , adenocarcinoma , radiation therapy , surgery , clinical trial
To investigate second-line chemotherapy in gemcitabine-pretreated patients with advanced or metastatic pancreatic cancer [(frequency, response, outcome, course of carbohydrate antigen 19-9 (CA 19-9)].
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom